Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Health Catalyst Inc’s stock clocked out at $3.95, down -2.23% from its previous closing price of $4.04. In other words, the price has decreased by -$2.23 from its previous closing price. On the day, 0.67 million shares were traded.
Ratios:
To gain a deeper understanding of HCAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.24. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.44.
On January 08, 2025, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when Benjamin Landry bought 3,255 shares for $3.63 per share.
Kevin Freeman bought 4,747 shares of HCAT for $17,254 on Jun 02 ’25. On Jun 02 ’25, another insider, Daniel LeSueur, who serves as the Officer of the company, bought 3,802 shares for $3.63 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.88 while its Price-to-Book (P/B) ratio in mrq is 0.73.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $3.49. The 50-Day Moving Average of the stock is -1.77%, while the 200-Day Moving Average is calculated to be -36.53%.
Shares Statistics:
A total of 69.48M shares are outstanding, with a floating share count of 66.22M. Insiders hold about 4.85% of the company’s shares, while institutions hold 80.04% stake in the company.
